Results for tag: "Tumor Infiltrating Lymphocytes"

The Tumor Infiltrating Lymphocytes (TILs) market is a segment of the broader immune disorders drugs field focused on a unique form of cancer treatment that harnesses the body's natural immune defenses. TIL therapy involves extracting immune cells that have penetrated tumorous tissues, expanding them outside the body to increase their numbers, and then infusing them back into the patient to fight the cancer. This approach uses the natural specificity of the immune system to target and destroy cancer cells. TIL therapies are considered a form of adoptive cell transfer, a category of advanced therapies that also includes CAR-T cell therapies. While TILs have shown promise in treating certain types of cancer, their development and application are challenged by the complexity of manufacturing, the need for personalized medicine, and the management of potential side effects. In the TIL market, several biotechnology and pharmaceutical companies are involved in the development and commercialization of therapies for various cancers. Notable entities include Iovance Biotherapeutics, which specializes in the development of novel cancer immunotherapies based on TILs; Kite Pharma, known for its work in cell therapy; and Lion Biotechnologies, a clinical-stage biopharmaceutical company focused on TIL therapy for solid tumors. Other companies active in this field are advancing the research and clinical development to expand the applicability and efficacy of TIL treatments. Show Less Read more